Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | LPL | P06858 | 13/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.37 |
| ▸ | CA1 | P00915 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.32 |
| ▸ | CA9 | Q16790 | 3/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4219113 | 0.82 | LPL (0.38) | ESR2LPLLIPG | |
| SCHEMBL1317499 | 0.82 | LPL (0.43) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL29813004 | 0.80 | ESR2 (0.35) | ESR2LPLLIPG | |
| SCHEMBL26967133 | 0.80 | ESR2 (0.35) | ESR2LPLLIPG | |
| SCHEMBL17667860 | 0.80 | ESR2 (0.39) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL26686295 | 0.79 | LPL (0.38) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL30633335 | 0.79 | LPL (0.38) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL2035675 | 0.79 | ESR2 (0.38) | ESR2LPLLIPGCA1CA2 | |
| SCHEMBL1335808 | 0.77 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL30169943 | 0.76 | ESR2 (0.36) | ESR2LPLLIPGCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198818-B2 | Brominated flame-retardant tetrazines | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 2021-12-14 | — | — | US | disclosed |
| US-20200399540-A1 | BROMINATED FLAME-RETARDANT TETRAZINES | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2020-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198818-B2 | Brominated flame-retardant tetrazines | PBRM1, NBAS, TIPRL | ESR2 2992/4885LPL 2373/4885LIPG 4056/4885 |
| US-20200399540-A1 | BROMINATED FLAME-RETARDANT TETRAZINES | PBRM1, NBAS, TIPRL | ESR2 2992/4885LPL 2373/4885LIPG 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.